Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335270 · ClinicalTrials.gov registry record · Phase 4
A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00335270 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 100 participants.
The verdict
NCT00335270, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the antiretroviral efficacy, safety, and tolerability of fos-amprenavir boosted with either of two doses of ritonavir (RTV) when administered in combination with ABC/3TC (abacavir/lamivudine, Epzicom®) FDC (fixed dose combination) in a once-daily regimen over 96 weeks in ART-naïve, HIV-infected adults
Interventions
- DRUG fos-amprenavir calcium, ritonavir
- DRUG abacavir/lamivudine as Epzicom
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00335270
The ClinicalTrials.gov registry entry for NCT00335270 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fos-amprenavir calcium, ritonavir is the first listed.
NCT00335270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00335270 about?
NCT00335270 is a clinical study titled "A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination". The purpose of this study is to evaluate the antiretroviral efficacy, safety, and tolerability of fos-amprenavir boosted with either of two doses of ritonavir (RTV) when administered in combination with ABC/3TC (abacavir/lamivudine, Epzicom®) FDC (fixed dose combination) in a once-daily regimen over...
What is the current status of trial NCT00335270?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2006-03. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00335270?
The interventions under investigation include: fos-amprenavir calcium, ritonavir (DRUG), abacavir/lamivudine as Epzicom (DRUG).
Who is sponsoring clinical trial NCT00335270?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.